Is It Time to Dump Your Shares of Pfizer?

Pfizer, following a pandemic-driven revenue surge to over $100 billion in 2022, has seen a significant decline to $63 billion due to waning COVID-19 product demand and key patent expirations, resulting in a nearly 50% stock drop over three years. To reignite growth, the company is implementing a $7 billion cost-saving plan, launching new non-COVID drugs projected to yield $20 billion by 2030, and acquired Seagen to expand its oncology portfolio. However, its strategic entry into the obesity drug market via a proposed acquisition of Metsera is now challenged by a competing bid from Novo Nordisk, creating near-term uncertainty, though analysts view the stock as reasonably priced for a gradual, long-term recovery.

Analysis

Pfizer's revenue peaked at over $100 billion in 2022, driven by its COVID-19 portfolio and blockbuster drugs like Eliquis and Ibrance. However, subsequent declines in COVID-19 product demand and patent expirations for key drugs led to a significant revenue drop to approximately $63 billion in the most recent full year. This downturn has resulted in a nearly 50% stock performance decline over the past three years.

To counteract these headwinds, Pfizer has initiated a cost realignment plan targeting over $7 billion in savings by 2027 and projects $20 billion in 2030 revenue from non-coronavirus product launches through H1 2024. The company also completed the acquisition of Seagen in 2023, aiming to bolster its oncology presence, with two Seagen products already showing double-digit growth.

Pfizer is strategically entering the high-demand obesity drug market, forecast to reach nearly $100 billion by decade-end, through a proposed acquisition of Metsera, which possesses a Phase 2 candidate. However, a competing bid from Novo Nordisk for Metsera introduces near-term uncertainty, despite Pfizer's stated intent to enforce its rights and deeming the rival proposal "illusory."

The company's transition to an improved cost structure and new product growth is a gradual, multi-year process, suggesting no immediate sharp revenue increase. Despite potential risks from the Metsera challenge or slower product growth, the overall outlook is considered bright, with Pfizer currently trading at approximately 8x forward earnings estimates, positioning it as reasonably priced for a long-term recovery.

Key Decisions for Investors

• Monitor Pfizer's progress on its $7 billion cost-saving plan and the revenue ramp-up of new non-coronavirus products, which are crucial for long-term growth.
• Closely watch developments regarding the Metsera acquisition and the competing bid from Novo Nordisk, as this M&A outcome will significantly impact Pfizer's entry into the obesity drug market.
• Consider Pfizer as a long-term hold for patient investors, given its current valuation at 8x forward earnings and the multi-year timeline for its strategic initiatives to fully materialize.